Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 3 | 1 | 4 |
| 1999 | 3 | 3 | 6 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 1 | 3 | 4 |
| 2004 | 2 | 7 | 9 |
| 2005 | 4 | 2 | 6 |
| 2006 | 1 | 5 | 6 |
| 2007 | 3 | 9 | 12 |
| 2008 | 3 | 3 | 6 |
| 2009 | 3 | 5 | 8 |
| 2010 | 5 | 6 | 11 |
| 2011 | 2 | 2 | 4 |
| 2012 | 4 | 6 | 10 |
| 2013 | 5 | 5 | 10 |
| 2014 | 5 | 7 | 12 |
| 2015 | 6 | 6 | 12 |
| 2016 | 4 | 9 | 13 |
| 2017 | 3 | 13 | 16 |
| 2018 | 4 | 10 | 14 |
| 2019 | 5 | 4 | 9 |
| 2020 | 3 | 9 | 12 |
| 2021 | 1 | 5 | 6 |
| 2022 | 4 | 9 | 13 |
| 2023 | 3 | 7 | 10 |
| 2024 | 2 | 6 | 8 |
| 2025 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e258751.
-
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May; 213(5):590-599.
-
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691.
-
Negative Predictive Value of a Prostate MRI in Black Men: Implications for Biopsy Decision-Making. J Urol. 2025 Jun; 213(6):713-721.
-
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Nat Genet. 2025 Feb; 57(2):334-344.
-
Organ-confined prostate cancer with negative surgical margins in an entirely-embedded radical prostatectomy is essentially non-lethal-a retrospective single-institutional study of 520 patients. Int Urol Nephrol. 2025 Apr; 57(4):1105-1112.
-
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 Dec; 201:110532.
-
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816.
-
Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. Cancer. 2024 Oct 01; 130(19):3305-3310.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.